Today: 30 June 2026
Browse Category

NASDAQ:NUVB 20 November 2025 - 12 January 2026

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

New York, Jan 12, 2026, 14:44 ET — Regular session underway Nuvation Bio Inc shares tumbled almost 18% on Monday following news of a licensing deal with Japan’s Eisai and initial sales data for its lung-cancer treatment. The stock slipped 17.7% to $6.62, after fluctuating between $8.34 and $6.32 on roughly 11.4 million shares traded.
Nuvation Bio (NUVB) Rockets to 3‑Year High as Wall Street Lifts Price Targets on IBTROZI Momentum – November 20, 2025

Nuvation Bio (NUVB) Rockets to 3‑Year High as Wall Street Lifts Price Targets on IBTROZI Momentum – November 20, 2025

Nuvation Bio Inc. has become one of the hottest tickers in biotech this week. On November 20, 2025, NUVB is trading near a three‑year high after a powerful earnings beat, accelerating uptake of its lung‑cancer drug IBTROZI™, and a wave of bullish analyst upgrades that continue to roll in today. Seeking Alpha+2Trefis+2 At the time of writing, Nuvation Bio shares trade around $7.15, up roughly 49% today, with an intraday high of $7.21 and heavy trading volume, extending a massive multi‑day rally. Quiver Quantitative
20 November 2025

Stock Market Today

Go toTop